1 / 42

MICR 201 Microbiology for Health Related Sciences

MICR 201 Microbiology for Health Related Sciences . Microbiology- a clinical approach by Anthony Strelkauskas et al. 2010 Chapter 19: Antibiotics. Why is this chapter important?. Antibiotics have changed the face of health care.

yvon
Download Presentation

MICR 201 Microbiology for Health Related Sciences

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MICR 201 Microbiology for Health Related Sciences Microbiology- a clinical approach by Anthony Strelkauskas et al. 2010 Chapter 19: Antibiotics

  2. Why is this chapter important? • Antibiotics have changed the face of health care. • They have drastically reduced the number of deaths due to infection. • Infectious disease are among the few diseases we can actually cure with drugs.

  3. Map for chapter 19

  4. What is an antibiotic? • Original term was used for antibacterial compounds produced by living microorganisms. • These were products of secondary metabolic pathways and served to defend the producer against other microbes in the environment. • Some of them were chemically modified. • Chemotherapeutics were entirely chemically synthesized compounds. • Today, the term “antibiotics” many times used for any drug inhibiting bacteria.

  5. Bacterial and fungal natural antibiotic producers

  6. Historical perspectives • No major discoveries of natural antibiotic substances have occurred for several years. • Efforts have now shifted to modifying existing antibiotics. • Searching in new places for potential antibiotics has also gained in prominence.

  7. Antibiotic spectra • The original natural molecules used by humans as antibiotics have a very narrow spectrum. • Penicillin activity is typically against Gram-positive bacteria. • Natural molecules can be chemically modified making it possible to broaden their spectrum. • Antibiotics are classified as either broad-spectrum or narrow-spectrum. • Broad spectrum antibiotics are active against a wide range of bacteria including Gram-positive and Gram-negative bacteria. • Ciprofloxacin is a broad spectrum antibiotic.

  8. Antibiotic targets • The ideal antibiotic should target structures and processes only found in the pathogen. • A fundamental criterion of antibiotics for medical use is selective toxicity. • The antibiotic should be destructive to the disease-causing organism but have no effect on the human host. • The first antibiotic discovered, penicilin, showed high selective toxicity. • Many antibiotic molecules are toxic if administered at high concentrations. • Toxicity necessitates extensive testing. • It can take years and cost millions of dollars.

  9. Antibiotic targets , rifampin • The bacterial cell wall • The bacterial plasma membrane • Synthesis of bacterial proteins • Bacterial nucleic acids • Bacterial metabolism

  10. Bacterial cell wall • The bacterial cell wall is built by many enzymatic reactions. • These enzymes can be used as targets of antibiotic molecules. • The cell wall is made up of the peptidoglycan molecules NAG and NAM. • They are cross-linked through activity of transglycosylase and transpeptidase enzymes. • Many antibiotics inhibit the activity of these two enzymes. • Results in improper cell wall cross-linking • Organism not able to withstand cell osmotic pressure. • Some antibiotics inhibit the production ofpeptidoglycan precursors molecules and their transport across the cell membrane.

  11. Bacterial cell wall: Penicillins • Penicillin-binding proteins (PBPs) are involved in the construction of the cell wall. • Penicillins contain a β-lactam ring which binds to these proteins. • New cell wall continuously built during active growth • Penicillin prevents the formation of an intact cell wall. • Penicillin is most effective during this phase. http://en.wikipedia.org/wiki/Beta-lactam_antibiotic

  12. Bacterial cell wall: Penicillins All forms of penicillin contain the b-lactam ring. • Chemically changing the side chain can change: • Antimicrobial activity • Resistance to stomach acid • Overall half-life in body • More than 50 derivatives

  13. Bacterial cell wall: Cephalosporins • Cephalosporins have similar activity to penicillins. • They prevent the construction of a stable cell wall. • Cephalosporins have a much greater affect on Gram-negative bacteria than penicillins because they can enter the porines of Gram-negative bacteria. • They are naturally broad spectrum antibiotics. • They are not susceptible to some of the β-lactamase enzymes. • Cephalosporins are frequently used both preoperatively and postoperatively. • Frequent use has increased resistance.

  14. Bacterial cell wall:Glycopeptide antibiotics • Glycopeptide antibiotics are derived from Streptomyces organisms. • Vancomycin is a glycopeptide antibiotic. • Glycopeptide antibiotics have serious side effects. • Toxicity level reduced in recent years by improving purification. • They inhibit cell wall synthesis by forming a complex with the substrates that make up peptidoglycan. • They cannot penetrate the porins of Gram-negative cells. • Narrow spectrum antibiotics restricted to Gram-positive bacteria. • Vancomycin used to be the drug of choice for MRSA. However, there are now vancomycin resistant S. aureus strains (VRSA) described.

  15. Bacterial cell wall:Isoniazid and Ethambutol for Tb • These antibiotics target mycolic acids and are used against Mycobacterium tuberculosis. • Their cell walls are modified by incorporation of mycolic acids. • Isoniazid inhibits the synthesis of mycolic acid. • Ethambutol inhibits the incorporation of mycolic acids into the cell wall. • Used in combination (plus rifampin) for Tb therapy.

  16. Bacterial plasma membrane • The plasma membrane is involved with important physiological functions. • It is a prime target for antibiotics. • Any disruption of the membrane destroys the bacteria. • Unfortunately the structure of the bacterial plasma membrane is similar to the eukaryotic plasma membrane. • This does not allow for selective toxicity. • One of the few antibiotics that target the bacterial cell membrane is polymyxin B. • Polymyxin B acts like a detergent.

  17. Synthesis of bacterial proteins • Ribosomes site of protein synthesis • Binding of mRNA, tRNA, decoding, peptide elongation, detachment • Disruption in production of protein devastating to cell. • Ribosomes of prokaryotes are not the same as eukaryotes. • 70S with 30S+50S • This allows for selective toxicity. • Eukaryotic cells have mitochondria ribosomes similar to prokaryotes. • There is antibiotic interference in eukaryotic cell function if antibiotics given in excessive amounts.

  18. Antibiotics that interfere with protein synthesis • Aminoglycosides • Gentamicin, tobramycin, spectinomycin, kanamycin, streptomycin • Tetracyclines • Tetracycline, doxycycline • Macrolide • Erythromycin, clarithromycin, azithromycin • Lincosamide • Clindamycin • Amphenicols • Chloramphenicol • Oxazolidinone • Linezolid • Streptogramins • Pristanamycin, streptogramin VRE

  19. Antibiotics that interfere with protein synthesis: Synercid® • Streptomyces species make pristinamycin and streptogramin. • They work synergistically to inhibit translation at the 50S subunit. • Both have been synthetically modified. • They make up the antibiotic Synercid®. • Approved for the treatment of vancomycin-resistant enterococci (VRE).

  20. Bacterial nucleic acids • DNA and RNA are universal components. • Their structure in bacteria is no different from their structure in humans. • This does not allow for selective toxicity. • Two families of synthetic compounds can target bacterial nucleic acids. • Rifamycins including rifampin inhibit transcription. • Used for Tb treatment • Quinolones including ciprofloxacin target bacterial topoisomerasegyrase and block DNA replication and DNA repair. • Used for urinary tract infections, osteomyelitis, community-acquired pneumonia and gastroenteritis, and anthrax

  21. Bacterial metabolism • Two targets for inhibiting bacterial growth: • Metabolic pathways at the plasma membrane. • Production of nucleic acid precursors; folic acid from para-aminobenzoic acid (PABA) • Humans consume folic acid with diet • Sulfa drugs block folic acid synthesis • Sulfa drugs use longer any antibacterial agent. • Sulfamethoxazole used in combination with trimethoprim; treat urinary tract infections.

  22. Antiviral drugs • Viruses pose a different set of problems for antibiotic therapy. • They are obligate intracellular parasites and use cell machinery for replication. • Drugs that can eliminate the virus are dangerous to non-infected cells. • This makes selective toxicity difficult. • Many viruses difficult to grow. • It is difficult to test potential antiviral drugs.

  23. Antiviral drugs • Many acute viral infections have a short duration. • The lack of rapid tests means it is difficult to differentiate between various viral infections. • Successful antiviral drugs must eliminate all virions. • The escape of even one virion could restart the infectious cycle.

  24. Antiviral drugs • Inhibition of uncoating • Amantadine for Influenza A virus infections • Nucleoside analogues block and terminate viral nucleic acid replication • Acyclovir (and Valtrex® and Famvir® ): Herpes simplex virus (HSV) infections • Gancyclovir: Cytomegalovirus (CMV) infections • Ribavirin: Lassa fever, Hantavirus infections, also Hepatitis C (in combination with INFa) • Nonnucleoside polymerase inhibitors • Foscarnet: HSV and CMV resistant to nucleoside analogues • Neuraminidase inhibitor • Zanamivir: Influenza virus

  25. Anti-HIV drugs • All anti-HIV drugs have numerous side effects • Common side effects include nausea, vomiting, headache, fatigue, weakness, and/or muscle pain. • Other side effects included changes in body fat distribution (lipodystrophy), inflammation, insomnia, and kidney disorders.

  26. Examples for lipodystrophy in AIDS patients http://drugster.info/medic/term/lipodystrophy-syndrome/

  27. Anti-HIV drugs • Reverse transcriptase inhibitors • Nucleoside analogues such as AZT (azidothymidine) • Prevent successful synthesis of cDNA by RT • Non-nucleoside analogue RT inhibitors • Bind non-competitively to RT to block its polymerization function • Nucleotide analogues • Work similar to the nucleoside analogues • Protease inhibitors • Prevent cleavage of polyproteins (by viral protease) required to make mature virus • Integrase inhibitors • Fusion inhibitors

  28. HAART • Combination therapy – helps prevent the development of resistant strains • HAART - highly active anti-retroviral therapy (3 or more different classes of drugs in combination) • Serious long-term side effects • accumulation of lactic acid in the bloodstream • physical and metabolic changes that cause changes in fat distribution • cholesterol and glucose abnormalities that can lead to a risk of heart disease. • Long-term use of the drugs can also promote the development of drug-resistant strains of HIV.

  29. Survival rates with HAART http://emedicine.medscape.com/article/1533218-overview

  30. Antifungal drugs • The emergence of diseases that render a host immunocompromised has led to increased secondary fungal infections. • Drugs used for fungal infection have selective toxicity issues. • Fungi are eukaryotes. • Attacking common targets can cause serious side effects. • Major antifungal drugs • Griseofulvin • Polyenes (Amphotericin B) • Azoles (clotrimazole, miconazole, ketoconazole, fluconazole) • Other antifungal drugs • Flucytosine • Pentamidine

  31. Antifungal drugs:Griseofulvin • Griseofulvinis produced by a species of the fungus Penicillium. • Administered orally, effective superficial fungal infections. • React with keratin. • Blocks formation of microtubules. • Inhibits mitosis in fungi. http://www.myfootshop.com/detail.asp?condition=onychomycosis

  32. Antifungal drugs:Polyenes • Polyenes are produced by the soil bacterium Streptomyces. • They interact with sterols and increase the permeability of the plasma membrane. • They must be used with caution because of side effects. • Amphotericin B has high renal toxicity. • Serum levels are closely monitored

  33. Antifungal drugs: Azoles • Azoles inhibit the production of sterols. • Clotrimazoleand miconazole • Sold without a prescription • Routinely used topically against athlete’s foot and vaginal yeast infection • Ketoconazole • Is a broad spectrum derivative for systemic fungal infections • Can be taken orally • Less toxic than amphotericin B • Fluconazoleand itraconazole • Are the least toxic azoles • Widely used for systemic fungal infections

  34. Antifungal drugs:Other antifungal drugs • Flucytosineinterferes with DNA and RNA synthesis. • Taken up preferentially by fungi. • High level of toxicity in kidney and bone marrow • Pentamidinebind to fungal DNA. • Used in treatment of Pneumocystis pneumonia http://www.health-pic.com/pneumocystis-carinii-pneumonia-in-hiv/

  35. Drugs for protozoa • The development of drugs for parasitic infections has lagged behind. • Parasitic infections do not occur often in developed nations. • Low profit incentive for corporate drug company development. • Two widely used anti-parasitic drugs are: • Quinine • Metronidazole

  36. Drugs for protozoa:Quinine • Quinine has been used as a treatment for malaria since the 1600s • It has been chemically modified into several synthetic forms. • Chloroquine has been widely used.

  37. Drugs for protozoa:Metronidazole • Metronidazoleis one of the most widely used anti-protozoan drugs. • Sold under the name Flagyl® • It is the drug of choice for: • Vaginitis resulting from Trichomonas vaginalis • Giardiasis • Amebic dysentery. • It interferes with anaerobic metabolism. Trichomonas vaginalis

  38. Drugs for helminths • Anti-helminthic drugs have also been largely ignored until recently. • Affected populations were not found in developed countries. • The popularity of sushi has led to an increase in tapeworm infestations. • Increased world travel has also increased helminth infections. • Important drugs are • Niclosamide • Praziquantel • Mebendazole • Ivermectin

  39. Drugs for helminths:Tapeworm and flukes • Niclosamideis the choice of treatment for these infections. • Inhibits the production of ATP • Praziquantelis also the drug of choice for fluke diseases. • Increases the permeability of plasma membranes for Ca+2. • It induces muscle spasms in the worm and dislodges the worm. • This exposes antigenic sites for attack by the host immune system.

  40. Drugs for helminths:Pinworm and Ascariasis • Mebendazoleis used against these infections. • It disrupts microtubule formation. • This affects the motility of the worm. • Ivermectinis also used. • It paralyzes the worm. • This induces the worm to exit the body. http://microbeworld.org/images/stories/twip/ascaris_from_child.jpg

  41. Chapter 19 key concepts • There have been no new discoveries of natural antibiotics in decades. • Microorganisms produce toxic chemicals as part of their natural defense. • Antibiotics can be broad or narrow spectrum. • Chemical modification of natural antibiotics can broaden their spectrum. • Some bacteria produce an enzyme called beta-lactamase that inhibits the reactivity of penicillin. • Antibiotics must be selectively toxic but most antibiotics will have side effects.

  42. Chapter 19 key concepts The five prime targets for antibiotics are the cell wall, the plasma membrane, the ribosome, nucleic acids, and metabolic synthesis pathways. Viruses present problems for antibiotic treatment because they are obligate intracellular parasites and use the host machinery for replication. Antifungal drugs have serious side effects because fungi are eukaryotic cells. The development of new drugs is an expensive and time-consuming process. Drugs against parasitic protozoans and helminths have been slow to be developed because these infections occur mostly in developing countries.

More Related